JPMorgan Lifts Gilead Sciences, Inc. (GILD)'s Price Target To $145, Maintains Overweight Rating

Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares.

While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move from December 2025 to December 2026.

The adjustment reflects a 29% upside potential for Gilead Sciences, Inc. (NASDAQ:GILD) from its closing share price on September 22.

Overall, Wall Street analysts maintain a positive outlook for the stock, with a consensus Buy rating.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company engaged in the development of medicines to prevent and treat various life-threatening diseases, including HIV, viral hepatitis, and cancer.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Defense Stocks to Buy Right Now and 15 Stocks ChatGPT Predicts Could Make You Wealthy in 5 Years.

Disclosure: None.